CVRx to Present at the William Blair 44th Annual Growth Stock Conference
CVRx, a commercial-stage medical device company, announced that its management team will present at the William Blair 44th Annual Growth Stock Conference on June 5, 2024. The presentation is scheduled for 8:40am Central Time and will be available via live audio webcast on the company's investor relations page.
- CVRx will present at a prestigious investor conference, potentially enhancing visibility and investor interest.
- The live webcast allows for broader access, facilitating real-time engagement with investors and stakeholders.
- The announcement lacks detailed financial or clinical updates, leaving investors without new performance insights.
- A single event like this might not significantly impact the stock price without substantive updates.
MINNEAPOLIS, May 22, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that the management team will present at the William Blair 44th Annual Growth Stock Conference on Wednesday, June 5, 2024. The Company is scheduled to present at 8:40am Central Time the same day via webcast.
A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com.
About CVRx, Inc.
CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com
Media Contact:
Laura O’Neill
Finn Partners
402-499-8203
laura.oneill@finnpartners.com
FAQ
When will CVRx present at the William Blair 44th Annual Growth Stock Conference?
How can I access CVRx's presentation at the William Blair Growth Stock Conference?
What is the stock symbol for CVRx?
Why is CVRx presenting at the William Blair Growth Stock Conference?
